Bev Incledon, PhD

  • 2Articles
  • 16.4KReads1
  • 2019–2021Active
  • 10Collaborators
  • 15Citations2

About

Bev Incledon, PhD, is affiliated with Ironshore Pharmaceuticals & Development, Inc. in Camana Bay, Grand Cayman. Incledon has published research focused on neurodevelopmental and child and adolescent psychiatry, particularly examining functional responses and impairments in youth with ADHD. Contributions include studies on treatment optimization with DR/ER-MPH and normative data for behavioral functioning assessments in children. Collaborations frequently include Norberto J. DeSousa, Andrew J. Cutler, Ann C. Childress, F. Randy Sallee, and Floyd R. Sallee.

Publications

JCP
Original Research

Response and Remission with DR/ER-MPH

June 22, 2021

Delayed-release and extended-release methylphenidate (DR/ER-MPH) has shown marked improvement in ADHD symptoms and functional impairment. This post hoc analysis examined response and remission thresholds for DR/ER-MPH in the context...
, , , et al
JCP
Original Research

Norms for Time-Sensitive Measures of Function in ADHD

December 10, 2019

Children with ADHD often have functional impairments in the early morning and late afternoon and evening. This study sought to establish norms on 2 rating scales to help clinicians...
, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe